TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00005851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Undergo DLI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02686281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMC-252-L-Lysine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMC-252-L-Lysine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01859104

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Use of smartphone app
Study: NCT03702296

Intervention type: OTHER
Group type: OTHER
Intervention: Ear plugs and eye masks
Description: Patients in the intervention arm will be provided with ear plugs and eye masks and instructed on the use of these during sleep
Study: NCT00459979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Sunitinib will be dosed at 50 mg p.o. daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: nephrectomy
Study: NCT04895800

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytovive
Description: Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Natural Flavors \[Chocolate, Caramel, Vanilla Cream\], Silica, Inulin, Sucralose)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Caffeine (Green tea caffeine extract (170 mg; to deliver 34 mg caffeine \[20% natural caf-feine\])
Study: NCT03523000

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous intrathecal prognostic infusion test
Description: The patient is infused with solution through the percutaneous intrathecal catheter at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Continuous intrathecal prognostic infusion test
Description: The patient is infused with solution through the percutaneous intrathecal catheter at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
Study: NCT03966118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 1mg/kg Day 1 and Day 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 8mg/kg on Day 1 and Day 15 of a 28-day cycle
Study: NCT04199754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque 300mg/mL Solution for Injection
Description: Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cone Beam CT
Description: 60 seconds after contrast administration, a Cone Beam CT will be performed.
Study: NCT03966118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 on Day 1, Day 8 and Day 15 of a 28-day cycle
Study: NCT01825252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Intervention
Description: Approximately 20% of people are trained to have discussions endorsing less risky behaviors with members of their social network.
Study: NCT02666586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-pulse smoothie smoothie
Description: Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
Study: NCT02622971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PBMT
Description: Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PBMT
Description: Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PBMT
Description: Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PBMT
Description: Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.
Study: NCT02378064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-month treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-month treatment
Study: NCT01825252

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counsel, Test, and Treat
Description: People receive standard-of-care HIV/STD counseling, testing, and treatment
Study: NCT02378064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-month treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-month treatment
Study: NCT02763891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group (Body body suspension and tilting exercises)
Description: The body suspension and tilting exercise program (Chordata Method) involved suspending the body in the apparatus while performing tilting exercises. The Chordata apparatus consists of a steel structure with special springs and a harness specifically manufactured for practicing the Chordata Method. During the training sessions, the prescribed exercises emphasize the repetition of movements designed to promote different types of muscle contractions (concentric, eccentric, static) performed in different body positions and joint angles. Thus, when using the method, patients experience maximal functional performance beyond to the body mass centre, activating trunk antagonist muscles and motor memory evocation. Each session lasts 30 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group (global muscle stretching)
Description: Subjects receiving submitted a global muscle stretching session twice a week for eight weeks. During this period. All participants are requested to don't engage in any additional type of exercise program or physical activity throughout the study period.
Study: NCT02273505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin (ER)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Persantin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl salicylic acid (ASA)
Study: NCT04537338

Intervention type: GENETIC
Intervention: 1. Characterize the immune response after infection with SARS-CoV-2
Description: 1. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens

Intervention type: GENETIC
Intervention: 1. Characterize the immune response after infection with SARS-CoV-2
Description: 1. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens

Intervention type: GENETIC
Intervention: 1. Characterize the immune response after infection with SARS-CoV-2
Description: 1. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens
Study: NCT03615625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power Training Session
Description: 3 sets of 8-10 repetitions of 5 exercises performed in the following order: leg press, bench press, knee extension, upright row, and knee flexion, using an intensity corresponding to 50 % of 1-RM and two-minute intervals between sets and exercises. The concentric phase of exercises during each repetition was performed as fast as possible while the eccentric phase lasted 1-2 seconds.
Study: NCT04199754

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Saline
Description: 50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
Study: NCT00916721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
Study: NCT01654562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
Study: NCT01764178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livalo fixed combination drug
Description: Pitavastatin 4mg / Valsartan 160mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin, Valsartan
Description: Pitavastatin 4mg, Valsartan 160mg
Study: NCT04016493

Intervention type: PROCEDURE
Intervention: Connective tissue graft
Description: The patient received 600 mg of ibuprofen (paracetamol 1 g in case of allergy) prior to surgery, and chlorhexidine mouthwash 0.2% was provided for 2 min. Patients received local anaesthesia at the donor and recession sites (articaine hydrochloride 7200 mg/1.8 ml, adrenalin 1800 mcg/1.8 ml). CTG harvesting was performed prior to the preparation of the reception site to avoid any bias. The graft dimension was calculated according to the recession dimensions; a minimum of 3 mm of the graft was submerged mesially, distally and apically. The CTG was harvested from the palate with single edge incision and sutured with 4.0 silk. The patient was subsequently assigned randomly to the control (CAF+CTG) or the test group (TUN+CTG).

Intervention type: PROCEDURE
Intervention: Connective tissue graft
Description: The patient received 600 mg of ibuprofen (paracetamol 1 g in case of allergy) prior to surgery, and chlorhexidine mouthwash 0.2% was provided for 2 min. Patients received local anaesthesia at the donor and recession sites (articaine hydrochloride 7200 mg/1.8 ml, adrenalin 1800 mcg/1.8 ml). CTG harvesting was performed prior to the preparation of the reception site to avoid any bias. The graft dimension was calculated according to the recession dimensions; a minimum of 3 mm of the graft was submerged mesially, distally and apically. The CTG was harvested from the palate with single edge incision and sutured with 4.0 silk. The patient was subsequently assigned randomly to the control (CAF+CTG) or the test group (TUN+CTG).
Study: NCT03472534

Intervention type: DRUG
Group type: OTHER
Intervention: diacerein 1% ointment
Description: diacerein 1% ointment applied to the skin of the infrascapular area of the back under occlusive patch for 21 days.
Study: NCT01407562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
Study: NCT03501355

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle strength training
Description: Treatment group will receive inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 50% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 50% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle endurance training
Description: Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department.
Study: NCT00515463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denosumab
Description: 60 mg denosumab in 1mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denosumab
Description: 60 mg denosumab in 1mL
Study: NCT02369978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox
Description: Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benznidazole
Description: Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
Study: NCT02575482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVN-D4010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02886026

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder tumor resection using diathermia
Description: Conventional bladder tumor resection using diathermia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser (980 nm) tumor destruction
Description: Laser mediated destruction of bladder tumors (LMD-BT)
Study: NCT01395485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827 or Placebo
Description: A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827 or Placebo
Description: A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827 or Placebo
Description: A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827 or Placebo
Description: A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
Study: NCT01731691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: α1 Proteinase Inhibitor
Description: Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.
Study: NCT04109443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Men & Media Program
Description: The online sexual health media literacy website includes content about (1) male anatomy; (2) HIV/STI prevention; (3) overall sexual health; and (4) sexually explicit online media (SEOM) literacy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Available websites on safe sex and preventing STIs
Description: Available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections (STIs) including HIV.
Study: NCT01583192

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin preparation
Description: skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin preparation
Description: skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%
Study: NCT03950102

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Radiation dose of 27.5-50Gy in 5 fractions over 5-14 days with a radical dose as high as achievable based on mean liver dose (MLD), while fulfilling the dose constraints of OARs
Study: NCT05126225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma reduction
Description: The intervention is modularized to have eight weekly sessions of 2-hour group discussions, led by a trained facilitator. The facilitator applies the principle of CBT and provides psychoeducation to promote the awareness and understanding of HIV stigma as well as training to help participants acquire alternative coping skills, such as relaxation techniques.
Study: NCT02384369

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SNC-102 sustained release tablet
Description: Sustained release oral tablet of SNC-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNC-102 sustained release tablet
Description: Sustained release oral tablet of SNC-102
Study: NCT00073593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: 250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of surgery with the option to increase or decrease the infusion in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT) \>300 seconds (s).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: : Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of \>300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamine
Description: Per institutional practice. Batches from hospital stock.
Study: NCT03013751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Active drug